Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 11.9% during mid-day trading on Tuesday . The company traded as low as GBX 1.49 ($0.02) and last traded at GBX 1.58 ($0.02). 2,592,732 shares traded hands during trading, an increase of 45% from the average session volume of 1,784,130 shares. The stock had previously closed at GBX 1.79 ($0.02).
ImmuPharma Stock Performance
The company has a market capitalization of £6.70 million, a P/E ratio of -161.00 and a beta of 1.53. The business has a 50 day moving average of GBX 1.69 and a 200-day moving average of GBX 1.94.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- The 3 Best Blue-Chip Stocks to Buy Now
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What is a support level?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- High Dividend REITs: Are They an Ideal Way to Diversify?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
